Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus

NCT06062069 is registered in ClinicalTrials.gov with Carmot Therapeutics, Inc. as lead sponsor.

NCT NCT06062069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06062069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus
Lead sponsor
Carmot Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 19, 2023
Completion date
July 9, 2025
Enrollment
111 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

obese, overweight, type 1 diabetes mellitus